Royalty Pharma plc
RPRX
$33.35
$0.200.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.26B | 2.26B | 2.27B | 2.24B | 2.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.26B | 2.26B | 2.27B | 2.24B | 2.24B |
| Cost of Revenue | 21.72M | 732.46M | 491.91M | 996.65M | 1.03B |
| Gross Profit | 2.24B | 1.53B | 1.77B | 1.24B | 1.21B |
| SG&A Expenses | 289.72M | 236.67M | 228.27M | 228.78M | 221.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 363.45M | 971.13M | 722.18M | 1.28B | 1.30B |
| Operating Income | 1.90B | 1.29B | 1.54B | 960.19M | 939.40M |
| Income Before Tax | 1.77B | 1.33B | 1.71B | 1.03B | 1.19B |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.77K | 1.33K | 1.71K | 1.03K | 1.19K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -675.97M | -471.83M | -568.94M | -356.53M | -387.87M |
| Net Income | 1.09B | 858.98M | 1.15B | 673.24M | 798.86M |
| EBIT | 1.90B | 1.29B | 1.54B | 960.19M | 939.40M |
| EBITDA | -- | -- | 614.31M | 767.17M | 1.02B |
| EPS Basic | 2.34 | 1.81 | 2.56 | 1.51 | 1.79 |
| Normalized Basic EPS | 0.89 | 0.49 | 0.64 | 0.29 | 0.20 |
| EPS Diluted | 2.34 | 1.80 | 2.56 | 1.50 | 1.78 |
| Normalized Diluted EPS | 0.71 | 0.40 | 0.48 | 0.22 | 0.15 |
| Average Basic Shares Outstanding | 1.92B | 1.94B | 1.79B | 1.79B | 1.79B |
| Average Diluted Shares Outstanding | 2.36B | 2.38B | 2.38B | 2.39B | 2.40B |
| Dividend Per Share | 0.85 | 0.84 | 0.83 | 0.82 | 0.81 |
| Payout Ratio | 34.60% | 43.83% | 32.50% | 54.64% | 45.50% |